Abiraterone acetate, the active ingredient of ZYTIGA is the acetyl ester of abiraterone. Abiraterone is an inhibitor of CYP17 (17α-hydroxylase/C17,20-lyase). Each ZYTIGA tablet contains either 250 mg or 500 mg of abiraterone acetate.
ZYTIGA (ABIRATERONE ACETATE) INDICATIONS:
ZYTIGA is indicated in combination with prednisone for the treatment of patients with:
Metastatic castration-resistant prostate cancer (CRPC)
Metastatic high-risk castration-sensitive prostate cancer (CSPC)
DOSAGE FORM & STRENGTH:
Zytiga (abiraterone acetate) 250mg
Zytiga (abiraterone acetate) 500mg
Rasso Swiss Pharma is a Wholesaler, supplier and distributor for Zytiga (abiraterone acetate).